Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) just unveiled an announcement.
Zydus Lifesciences Limited has received final approval from the USFDA to manufacture Methenamine Hippurate Tablets USP, 1 gram, which are used for the prophylactic or suppressive treatment of frequently recurring urinary tract infections. This approval marks a significant milestone for Zydus, enhancing its product portfolio in the U.S. market, where these tablets had annual sales of USD 32.6 million. The approval reflects Zydus’s continued expansion in the pharmaceutical sector, with the company having secured 419 approvals and filed 483 ANDAs since FY 2003-04.
More about Zydus Lifesciences Limited
Zydus Lifesciences Limited is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of medical products. The company is known for its commitment to innovation and has a significant presence in the global market, particularly in the United States.
YTD Price Performance: -7.57%
Average Trading Volume: 46,386
Current Market Cap: 905.5B INR
See more insights into ZYDUSLIFE stock on TipRanks’ Stock Analysis page.